Skribe Medical
A wearable cardio-oncology platform designed to monitor cardiac function and cardiotoxicity in cancer patients and clinical trials.
Skribe Medical is a biotech & life sciences company based in US. It has raised $1.65 million in disclosed funding. Its latest round was a Pre-seed of $1.65 million in November 2026.
Overview
Skribe Medical develops a wireless wearable sensor system for the cardio-oncology sector, aiming to assist oncologists in monitoring cardiac function and cardiotoxicity [0]. By facilitating rapid assessment of Left Ventricular Ejection Fraction (LVEF) in clinical or home settings, the platform helps prevent delays in cancer treatment caused by cardiac monitoring bottlenecks [0]. The technology features a "Resonant Body Power" system, which utilizes a battery-free sensor design intended to improve patient comfort without compromising clinical accuracy [0]. Beyond clinical care, Skribe targets oncology clinical trials, offering tools to detect cardiotoxicity signals earlier and gather physiological datasets [0]. The company has raised $1.65 million in pre-seed funding to support its operations in the healthtech and biotech spaces [Registry]. The platform provides a streamlined alternative to traditional imaging, allowing for potentially continuous or more frequent cardiac health insights during cancer treatment cycles [0].
Funding
Total disclosed: $1.6M across 1 round. Computed only from sourced rounds.
| Date | Company | Amount | Stage | Lead | Other investors | Sector | Sources |
|---|---|---|---|---|---|---|---|
| $1.6M | Pre-seed | SeaX Ventures | GoAhead Ventures +1 | Biotech & Life Sciences | 2 |
Investors
Questions and answers
What does Skribe Medical do?
A wearable cardio-oncology platform designed to monitor cardiac function and cardiotoxicity in cancer patients and clinical trials.
How much has Skribe Medical raised?
Skribe Medical has raised $1.65 million in disclosed funding across 1 round tracked by OSH.
Who has invested in Skribe Medical?
Investors in Skribe Medical include SeaX Ventures, GoAhead Ventures, and Marin Sonoma Impact Ventures.
Sources
- 1.SeaX Ventures bets US$1.65M on Skribe Medical’s AI heart patch for cancer patients — e27, Nov 12, 2026
- 2.Skribe Medical advances wearable heart monitoring for cancer patients following selection for FDA innovation program — Cision PR Newswire, Nov 11, 2026 · Press release
- 3.Skribe Medical · Official
- 4.Skribe Medical · Official